Evidence map›Paper›PMID 10698522›Full record

ArticleOncogene2000

A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells.

W L Blalock, M Pearce, L S Steelman, R A Franklin, S A McCarthy, H Cherwinski, M McMahon, J A McCubrey

Open access · bronzeAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 75 citations in OpenAlex.

  1. Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal transduction and targeted therapy · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

W L BlalockDepartment of Microbiology and Immunology, East Carolina University School of Medicine, Greenville, North Carolina 27858, USA.
M Pearce
L S Steelman
R A Franklin
S A McCarthy
H Cherwinski
M McMahon
J A McCubrey
East Carolina University · USCellular Research (United States) · US

Funding

NCI NIH HHS R01CA15025
6 · The paper itself

Abstract

The Raf/MEK/MAP kinase cascade plays a critical role in transducing growth signals from activated cell surface receptors. Using deltaMEK1:ER, a conditionally-active form of MEK1, we demonstrate the ability of this dual specificity protein kinase to abrogate the cytokine-dependency of the human and murine hematopoietic cells lines TF-1, FDC-P1 and FL5.12. Cytokine-independent cells were obtained from TF-1, FDC-P1 and FL5.12 cells at frequencies of 2.5 x 10(-3), 5 x 10(-5) and 10(-7) respectively, indicating that not all cells expressing deltaMEK1:ER were factor-independent. In general, cells that were converted to a cytokine-independent phenotype displayed a higher level of MAP kinase activity in response to deltaMEK1:ER activation than those that remained cytokine-dependent. deltaME-K1:ER-responsive cells could be maintained long-term in the presence of beta-estradiol as well as the estrogen-receptor antagonist 4-Hydroxy-Tamoxifen and the anti-estrogen ICI 164383. Removal of hormone led to the rapid cessation of cell growth in a manner similar to that observed when cytokine is withdrawn from the parental cells. Treatment of deltaMEKI:ER-responsive cells with a specific and selective inhibitor, PD98059, prevented growth in response to beta-estradiol. GM-CSF mRNA transcripts were detected in the MEK1-responsive cells indicating that the activated deltaMEK1:ER may induce a pathway leading to autocrine proliferation. Treatment of MEK1-responsive cells with an anti-GM-CSF antibody, but not a control antibody, suppressed cell growth. The cell lines described here will be useful for elaborating the ability of the MAP kinase pathway to regulate cell proliferation in hematopoietic cells.

Indexed as

Autocrine CommunicationMAP Kinase Signaling SystemAnimalsAntibodies, MonoclonalCell DivisionCell LineCell Transformation, NeoplasticCytokinesEnzyme ActivationEnzyme InductionEstradiolFlavonoidsGenes, SyntheticGranulocyte-Macrophage Colony-Stimulating FactorHematopoietic Stem CellsHumans2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-oneafimoxifeneAntibodies, MonoclonalCytokinesEstradiolFlavonoidsGranulocyte-Macrophage Colony-Stimulating FactorMAP2K1 protein, humanMap2k1 protein, mouseMAP Kinase Kinase 1Mitogen-Activated Protein Kinase KinasesProtein Serine-Threonine KinasesReceptors, EstrogenRecombinant Fusion ProteinsTamoxifen

Identifiers

PMID10698522
OpenAlexW2335275228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.